Inflammation and immune activation in antiretroviral-treated human immunodeficiency virus type 1-infected African infants and rotavirus vaccine responses

Priyanka Uprety, Jane C. Lindsey, Myron J. Levin, Kaitlin Rainwater-Lovett, Carrie Ziemniak, Mutsa Bwakura-Dangarembizix, Susan S. Kaplan, Micki Nelson, Amanda Zadzilka, Adriana Weinberg, Deborah Persaud

Research output: Contribution to journalArticlepeer-review

Abstract

Biomarkers of inflammation and immune activation were correlated with rotavirus vaccine responses in 68 human immunodeficiency virus type 1 (HIV-1)-infected (and 116 HIV-exposed but uninfected (HEU) African infants receiving pentavalent rotavirus vaccine (RV5) in a clinical trial. Prevaccination, HIV-1+ infants had significantly higher concentrations of interferon γ (IFNγ), interleukin1β, interleukin 2, interleukin 6, interleukin 10 (IL-10), and soluble CD14 compared with HEU infants. Postvaccination concentrations of neutralizing antibodies to RV5 were negatively correlated with prevaccination concentrations of IL-10 (RV5 surface proteins G1 and P1) and IFNγ (G1) in the HIV-1+ infants, whereas antirotavirus immunoglobulin A (IgA) levels were not. Heightened inflammation and immune activation in HIV-1+ infants did not alter IgA responses associated with protection from rotavirus disease.

Original languageEnglish (US)
Pages (from-to)928-932
Number of pages5
JournalJournal of Infectious Diseases
Volume215
Issue number6
DOIs
StatePublished - Mar 15 2017

Keywords

  • Antiretroviral therapy
  • Immune activation
  • Inflammation
  • Perinatal HIV-1 infection
  • Rotavirus vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Inflammation and immune activation in antiretroviral-treated human immunodeficiency virus type 1-infected African infants and rotavirus vaccine responses'. Together they form a unique fingerprint.

Cite this